Al Bristow works with our team of corporate and business transactions lawyers, focusing on life sciences transactions and emerging growth businesses. For more than 15 years, Al has served as either in-house or outside counsel to growing businesses in the pharmaceutical industry. He has senior-level management experience with private, pre-IPO, and public companies, specializing in development, collaboration, and license arrangements; commercial manufacturing and other transaction agreements; acquisitions and divestitures; and general corporate and compliance matters.
Before returning to Morgan Lewis in 2019, Al served for more than five years as vice president, associate general counsel at Catalent Pharma Solutions, where he was a member of Catalent’s senior leadership team. He was the lead attorney responsible for supporting the company’s Softgel Technologies business unit. While at Catalent, Al negotiated, drafted, and provided counsel to senior management and business partners on a variety of complex transactional matters, including pharmaceutical development and commercial manufacturing agreements and intellectual property licensing arrangements for both branded and generic products. Al also supported Catalent’s mergers and acquisitions (M&A) activities, including due diligence and postclosing integration.
Prior to that, Al was general counsel and corporate secretary at Barrier Therapeutics, a specialty pharmaceutical company, where he was a member of Barrier’s senior management team. He was responsible for management and oversight of all legal matters affecting the company, a spinoff of Johnson & Johnson. Al counseled management and board members on various matters, including compliance, risk management, corporate governance, and fiduciary duties. While at Barrier, Al was in-house counsel to the team that took the company public; grew the organization from a development company to a commercial organization, including by building its salesforce and launching NDA products; and eventually sold the company to Stiefel Laboratories.
Earlier in his career, Al was an associate in the firm’s business and finance practice, where he represented biotech and pharmaceutical companies in collaboration and license agreements, product acquisitions, and divestitures, and emerging growth technology companies in venture capital financings, M&A transactions, and initial public offerings.
Acquisition and license from a pharma company of its compound optimization and screening technology.
License agreement for drug delivery tableting technology and equipment.
License agreement for an exclusive license to taste-masking technology to be applied to oral pharmaceutical, over-the-counter, and nutraceutical formulations.
Collaboration agreement to jointly provide an integrated service offering to early-stage developers of oral controlled-release products.
Joint venture with a Chinese biotechnology company for the manufacture of VMS softgel capsules in China.
Acquisition of an Australia-based pharmaceutical packaging business.
Acquisition of a Brazil-based developer and manufacturer of VMS, over-the-counter, and prescription products.
Acquisition of a Canada-based developer and manufacturer of over-the-counter, high-potency, and other prescription products, including related technology licensing.
License, development, and commercial supply agreement for a modified-release capsule product using Catalent’s softgel technology.
License, development, and commercial supply agreement for birth control capsules.
Collaboration and license agreement for the formulation and development of a portfolio of products for treating production and companion animals.
Development and commercial supply agreement for the manufacture of capsules containing pesticides and pharmaceuticals to be applied topically to livestock.
Development and commercial supply agreement for the manufacture and supply of a proprietary extended-release prescription product utilizing Catalent’s modified-release drug delivery platform.
Commercial supply agreement for the manufacture of proprietary hormone therapy drug candidates.
Amendment and restatement and ongoing management of collaboration, license, and supply agreement with respect to the development, manufacture, and supply of a leading over-the-counter product using Catalent’s softgel technology platform.
Several other long-term contracts for development, clinical and commercial supply, and intellectual property and regulatory filing licenses, with a broad range of industry-leading “Big Pharma” brand and generic companies..
University of Pennsylvania Law School, 1995, J.D.
Lafayette College, 1992, B.A., Economics & Business, Government & Law, magna cum laude